About teqcool

TEQCool AB is a medical technology company in Lund, Sweden. TEQCool develops a unique, patented solution for selectively cooling the brain of patients with severe brain injury suffering from neurogenic fever.


The intended therapy is based on many years of research and development at Lund University, pre-clinical and clinical studies as well as technical development by TEQCool’s engineers.


5-6 million people suffer from severe TBI (Traumatic Brain Injury) per year with approximately 110 000 deaths in the US and Europe. Severely brain-injured patients with refractory fever, is a vulnerable patient group with poor prognosis. TEQCool’s main focus is severe TBI, where temperature control can both reduce fever and the intracranial pressure, to improve functional outcome, reduce mortality and length-of-hospital stay. This patient group is treated at Neuro-ICUs with cooling treatments poorly fitted to their needs.



TEQCool’s vision is to preserve patients’ brain function with targeted brain temperature control. This we aim to reach in strategic phases:

  • develop and launch brain normothermia therapy for severe brain injury patients


  • develop the therapy to fit patients that do not have an intracranial temperature monitoring system


  • establish brain normothermia as gold standard across indications where temperature control is established

Unique market opportunity

The global market for therapeutic temperature management is estimated to exceed 10 billion SEK per year.


The primary objective of temperature control is to preserve the patient’s neurogenic function. Existing systems cool the body in various ways and only secondarily the brain. TEQCool’s unique solution directly cools the brain via the nasal cavity. This selective and rapid brain cooling has the potential to transforming the temperature control market and establish a new treatment standard.


Masoud Khayyami


Masoud Khayyami, PhD in applied biochemistry from LTH, Lund University. Masoud has solid experience from research within medical technology and biotechnology. He is the principal owner and CEO of Cardeon AB.  Previously, he has been the CEO of SpectraCure AB.  Masoud has entrepreneurial experience in companies such as Lumito AB, Gasporox AB and Prolight Diagnostics AB.

Johannes Swartling

Johannes has a doctorate in physics from Lund University and is CTO at SpectraCure AB. He has extensive experience in commercializing research results in the role of CTO at SpectraCure and as former CTO at Gasporox and Neola Medical. Johannes is also CEO and board member of Deep Light Vision AB. He has also been a board member of SpectraCure, Neola Medical and NanoEcho.

Johan Gagner


Johan has a master’s degree in Automatic control at Lund University of Technology and is Development Director at Sever Pharma Solutions. He has extensive experience in product development, industrialization and design & technology transfer of medical devices and disposable products through various R&D management positions at Gambro, Hemocue a Danaher Company and Essity.


Niklas Marklund

MD, Ph.D. Professor of Neurosurgery at Dept of Clinical Sciences, Lund University, Sweden

Niklas Marklund, professor at the Department of Neurosurgery at Lund University, is new Medical Advisor for TEQCool. Professor Marklund is a leading expert in Traumatic Brain Injury and his clinical research involves the whole spectrum of the disease. He is the vice-president and co-founder of the European Neurotrauma Organisation (ENO), elected member of the Scandinavian Neurotrauma Committee and the Neurotrauma section of the World Federation of Neurological Surgery (WFNS), and the previous Trauma Section Chair (2017-2021) of the European Association of Neurosurgical Societies (EANS). Dr Marklund is on the editorial board of several scientific journals and a European editor of Journal of Neurotrauma.